In the last decades the pharmacological treatment of obsessive-compulsive disorder (OCD) has been significantly promoted by the effectiveness of selective serotonin (5-HT) reuptake inhibitors (SSRIs) and the subsequent development of the 5-HT hypothesis of OCD. However, since a large majority of patients (between 40% and 60 %) do not respond to SSRIs or strategies based on the modulation of the 5-HT system, it is now essential to search for other possible therapeutic targets.
Titolo: | The glutamate and the immune systems: new targets for the pharmacological treatment of OCD | |
Autore/i: | Marazziti, Donatella; Albert, Umberto; Mucci, Federico; Piccinni, Armando | |
Autore/i Unibo: | ||
Anno: | 2018 | |
Rivista: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.2174/0929867324666171108152035 | |
Abstract: | In the last decades the pharmacological treatment of obsessive-compulsive disorder (OCD) has been significantly promoted by the effectiveness of selective serotonin (5-HT) reuptake inhibitors (SSRIs) and the subsequent development of the 5-HT hypothesis of OCD. However, since a large majority of patients (between 40% and 60 %) do not respond to SSRIs or strategies based on the modulation of the 5-HT system, it is now essential to search for other possible therapeutic targets. | |
Data stato definitivo: | 2018-02-25T18:26:40Z | |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.